13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q1 2022. See the latest, Q2 2026 →
Reported value
$3.08B
−26% on the quarter before
Positions
60
3 new · 1 sold out
Top 10
78.2%
of the value
Est. gain
−$1.07B
on stocks held all quarter
Est. return
−27.8%
on those stocks since Q4 2021
Positions as of Mar 31, 2022, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2021. Striped tiles are options.
Largest buys
Since Q4 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Dexcom Inc~$177.3MAdded · 9.1% → 17.4%+346,584 shares
- Snowflake~$122.7MNew · 0.0% → 4.0%+535,604 shares
- Rani Therapeutics Hldgs Inc~$9.6MNew · 0.0% → 0.3%+714,471 shares
- Benson Hill Inc~$1.9MAdded · 2.6% → 1.6%+600,000 shares
- Cue Health Inc~$174,000New · 0.0% → 0.0%+27,000 shares
- Relay Therapeutics Inc~$137,080Added · 1.2% → 1.5%+4,580 shares
Largest sells
Since Q4 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Toast~$175.2MCut · 8.0% → 1.0%−8,064,224 shares
- Vera Therapeutics Inc~$9.7MCut · 0.5% → 0.2%−412,078 shares
- SentinelOne~$4.5MCut · 0.2% → 0.0%−117,272 shares
- Uber~$2.1MSold out · 0.1% → 0.0%−49,466 shares
- Rapt Therapeutics Inc~$1.9MCut · 0.6% → 0.4%−87,492 shares
- Vaccitech Plc~$991,646Cut · 0.5% → 0.3%−190,700 shares
- Twilio~$10,870Cut · 0.0% → 0.0%−66 shares
Holdings
As of Mar 31, 2022. Changes are in shares against Dec 31, 2021, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dexcom IncCOM · shares +49% · price −4.7% | 17.4% | $537.5M | −$17.9M | ||||||||
| UiPathCL A · shares 0% · price −49.9% | 9.9% | $303.7M | −$303.0M | ||||||||
| IonQCOM · shares 0% · price −23.6% | 9.1% | $279.5M | −$86.3M | ||||||||
| Verve Therapeutics IncCOM · shares 0% · price −38.1% | 8.1% | $250.4M | −$154.2M | ||||||||
| Oscar Health IncCL A · shares 0% · price +27.0% | 7.8% | $239.7M | +$51.0M | ||||||||
| Lyft IncCL A COM · shares 0% · price −10.1% | 7.6% | $235.7M | −$26.6M | ||||||||
| Eqrx IncCOM · shares 0% · price −39.4% | 6.4% | $196.4M | −$127.9M | ||||||||
| Planet Labs PbcCOM CL A · shares 0% · price −17.4% | 5.3% | $162.3M | −$34.2M | ||||||||
| SnowflakeCL A · shares New | 4.0% | $122.7M | — | ||||||||
| Arcus Biosciences IncCOM · shares 0% · price −22.0% | 2.6% | $80.9M | −$22.8M | ||||||||
| Freshworks IncCLASS A COM · shares 0% · price −31.8% | 2.3% | $72.3M | −$33.7M | ||||||||
| RobinhoodCOM CL A · shares 0% · price −23.9% | 2.2% | $66.6M | −$20.9M | ||||||||
| Desktop Metal IncCOM CL A · shares 0% · price −4.2% | 1.7% | $52.4M | −$2.3M | ||||||||
| Benson Hill IncCOMMON STOCK · shares +4.1% · price −55.7% | 1.6% | $49.6M | −$59.9M | ||||||||
| Relay Therapeutics IncCOM · shares +0.3% · price −2.5% | 1.5% | $47.0M | −$1.2M | ||||||||
| ToastCL A · shares −85% · price −37.4% | 1.0% | $31.1M | −$18.6M | ||||||||
| Lyell Immunopharma IncCOM · shares 0% · price −34.8% | 0.96% | $29.6M | −$15.8M | ||||||||
| Adagio Therapeutics IncCOM · shares 0% · price −37.2% | 0.84% | $25.9M | −$15.3M | ||||||||
| 23andme Holding CoCLASS A COM · shares 0% · price −42.5% | 0.84% | $25.8M | −$19.1M | ||||||||
| Sana Biotechnology IncCOM · shares 0% · price −46.6% | 0.75% | $23.2M | −$20.3M | ||||||||
| Monte Rosa Therapeutics IncCOM · shares 0% · price −31.3% | 0.67% | $20.5M | −$9.4M | ||||||||
| Illumina IncCOM · shares 0% · price −8.2% | 0.61% | $18.7M | −$1.7M | ||||||||
| Beam Therapeutics IncCOM · shares 0% · price −28.1% | 0.60% | $18.4M | −$7.2M | ||||||||
| Science 37 Holdings IncCOM · shares 0% · price −57.1% | 0.56% | $17.3M | −$23.1M | ||||||||
| Enjoy Technology IncCOM · shares 0% · price −17.8% | 0.54% | $16.5M | −$3.6M | ||||||||
| Total · 60 positions | 100% | $3.08B | −$1.07B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2021 to Q1 2022: 57 stocks held throughout, down $1.07B (−27.8%).
- Oscar Health Inc+$51.0M+27%
- Fulcrum Therapeutics Inc+$1.5M+34%
- Benson Hill Inc−$59.9M−56%
- IonQ−$86.3M−24%
- Eqrx Inc−$127.9M−39%
- Verve Therapeutics Inc−$154.2M−38%
- UiPath−$303.0M−50%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |